<DOC>
	<DOCNO>NCT00179465</DOCNO>
	<brief_summary>The purpose study determine whether treatment tiagabine ( Gabitril ) early course schizophrenia fundamentally correct brain deficit associate disease . This study fund National Institutes Health .</brief_summary>
	<brief_title>Treating Schizophrenia Correcting Abnormal Brain Development</brief_title>
	<detailed_description>It hypothesize enhancement GABA neurotransmission early course illness tiagabine ( Gabitril ) , GABA transporter GAT-1-specific inhibitor FDA-approved anticonvulsant , improve clinical symptom work memory schizophrenia . This improvement postulate result tiagabine-mediated modification developmental synaptic pruning prefrontal cortical circuitry . The occurrence circuitry modification tiagabine treatment assess follow independent methodologic approach : MRI morphometric analysis prefrontal gray matter volume fMRI measurement brain activity pattern performance task probe work memory .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Tiagabine</mesh_term>
	<criteria>Meets criteria diagnosis schizophrenia , onset psychotic symptom within past 3 year . Currently secondgeneration antipsychotic least 3 month . Age 1825 , otherwise healthy . Diagnosis schizoaffective disorder . Has fail two clinically adequate antipsychotic trial . History seizures neurologic disorder . Pregnant nursing woman . Known HIV infection . Actively suicidal . History substance dependence . Currently meet criterion substance abuse/dependence . Other MRI exclusion criterion per Radiology Department protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Treatment</keyword>
	<keyword>fMRI</keyword>
	<keyword>Cognition</keyword>
	<keyword>Brain development</keyword>
</DOC>